Glenmark Life Sciences Limited Share Price Bombay S.E.

Equities

GLS

INE03Q201024

Pharmaceuticals

Market Closed - Bombay S.E. 03:41:13 26/04/2024 pm IST 5-day change 1st Jan Change
813.9 INR +8.21% Intraday chart for Glenmark Life Sciences Limited +1.43% +23.86%
Sales 2024 22.83B 274M Sales 2025 * 25.79B 309M Capitalization 99.85B 1.2B
Net income 2024 4.71B 56.48M Net income 2025 * 5.5B 66.01M EV / Sales 2024 4.17 x
Net cash position 2024 * 3.5B 41.96M Net cash position 2025 * - 0 EV / Sales 2025 * 3.87 x
P/E ratio 2024
20.2 x
P/E ratio 2025 *
18.2 x
Employees 1,824
Yield 2024 *
2.59%
Yield 2025 *
2.95%
Free-Float 15.72%
More Fundamentals * Assessed data
Dynamic Chart
1 day+8.21%
1 week+1.43%
Current month+4.98%
1 month+4.99%
3 months-2.96%
6 months+30.39%
Current year+23.86%
More quotes
1 week
743.60
Extreme 743.6
856.20
1 month
743.60
Extreme 743.6
856.20
Current year
654.00
Extreme 654
904.20
1 year
495.10
Extreme 495.1
904.20
3 years
369.00
Extreme 369
904.20
5 years
369.00
Extreme 369
904.20
10 years
369.00
Extreme 369
904.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 13/19/13
Director of Finance/CFO - 01/22/01
Compliance Officer - 23/21/23
Members of the board TitleAgeSince
Director/Board Member 66 30/20/30
Chief Executive Officer 58 13/19/13
Human Resources Officer 49 11/18/11
More insiders
Date Price Change Volume
26/24/26 813.9 +8.21% 42,632
25/24/25 752.2 -8.96% 21,286
24/24/24 826.2 -0.13% 4,643
23/24/23 827.3 -1.44% 4,652
22/24/22 839.4 +4.61% 4,346

Delayed Quote Bombay S.E., April 26, 2024 at 03:41 pm IST

More quotes
Glenmark Life Sciences Limited is an India-based company that is primarily engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients (API). The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
815 INR
Average target price
905.8 INR
Spread / Average Target
+11.14%
Consensus

Quarterly revenue - Rate of surprise